ATA3219

ATA3219 is an investigational allogeneic chimeric antigen receptor (CAR) T-cell therapy developed by Atara Biotherapeutics. It consists of Epstein-Barr virus (EBV)-sensitized, unedited human T lymphocytes engineered to express a CAR targeting the CD19 antigen, which is present on most B cells implicated in B-cell mediated autoimmune diseases and certain B-cell malignancies. The therapy is designed to deplete CD19+ B cells, thereby addressing the root cause of diseases such as systemic lupus erythematosus (SLE), lupus nephritis (LN), and relapsed/refractory B-cell non-Hodgkin lymphoma. Key features include off-the-shelf availability, a 1XX costimulatory domain for enhanced expansion and reduced exhaustion, preserved endogenous TCR for persistence, and avoidance of gene editing to mitigate risks associated with alloreactivity[1][2][3][6].

Other names

allogeneic anti-CD19 CAR T cells ATA3219